{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T17:10:04Z","timestamp":1769361004996,"version":"3.49.0"},"reference-count":56,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegener. Dis. Manag."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.2217\/nmt-2021-0006","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T08:23:24Z","timestamp":1616401404000},"page":"193-206","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Opicapone for Parkinson\u2019s Disease: Clinical Evidence and Future Perspectives"],"prefix":"10.1080","volume":"11","author":[{"given":"Cl\u00e9mence","family":"Leung","sequence":"first","affiliation":[{"name":"Parkinson Toulouse Expert Centre Toulouse University Hospital\rToulouse\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[{"name":"Department of Neurosciences Clinical Investigation Center CIC 1436 Parkinson Toulouse Expert Center NS-Park\/FCRIN Network and NeuroToul COEN Center Toulouse University Hospital\rToulouse\rFrance"},{"name":"INSERM\rParis\rFrance"},{"name":"University of Toulouse 3\rToulouse\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7250-592X","authenticated-orcid":false,"given":"Margherita","family":"Fabbri","sequence":"additional","affiliation":[{"name":"Department of Neurosciences Clinical Investigation Center CIC 1436 Parkinson Toulouse Expert Center NS-Park\/FCRIN Network and NeuroToul COEN Center Toulouse University Hospital\rToulouse\rFrance"},{"name":"INSERM\rParis\rFrance"},{"name":"University of Toulouse 3\rToulouse\rFrance"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3299"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26082"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26125"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25364"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.7.10.1399"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0599-2"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"issue":"4","key":"e_1_3_3_10_1","first-page":"Cd004554","article-title":"Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson\u2019s disease","author":"Deane KH","year":"2004","unstructured":"Deane KH , SpiekerS, ClarkeCE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson\u2019s disease. Cochrane Database Syst. Rev.4, Cd004554 (2004).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt-2016-0022"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27475"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1767580"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002109900168"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22037"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10508"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000258660.74391.c1"},{"issue":"7","key":"e_1_3_3_18_1","first-page":"Cd007166","article-title":"Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson\u2019s disease patients with motor complications","author":"Stowe R","year":"2010","unstructured":"Stowe R , IvesN, ClarkeCEet al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson\u2019s disease patients with motor complications. Cochrane Database Syst. Rev. (7), Cd007166 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70225-X"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70073-4"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/nmt.15.46"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S137740"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25751"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150700"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.1.81"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23517"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)61511-5"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.57.2.263"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03081-x"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0343-0"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410210610"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1701-2"},{"key":"e_1_3_3_35_1","first-page":"S180","article-title":"A Phase I study of opicapone pharmacokinetics and its effects on COMT activity and levodopa pharmacokinetics in patients with stable Parkinson\u2019s disease","volume":"86","author":"Loewen GLP","year":"2019","unstructured":"Loewen GLP , OlanowWC, KieburtzKDet al. A Phase I study of opicapone pharmacokinetics and its effects on COMT activity and levodopa pharmacokinetics in patients with stable Parkinson\u2019s disease. Ann. Neurol., 86, S180 (2019).","journal-title":"Ann. Neurol."},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00336-1"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4703"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28322"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13914"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005557"},{"issue":"2","key":"e_1_3_3_41_1","first-page":"S88","article-title":"An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson\u2019s disease \u2013 Comfort-PD study part 2","volume":"34","author":"Takeda ATR","year":"2019","unstructured":"Takeda ATR , TsuboiY, NomotoM, MaedaT, NishimuraA, HattoriN. An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson\u2019s disease \u2013 Comfort-PD study part 2. Mov. Disord., 34(S2), S88 (2019).","journal-title":"Mov. Disord."},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-020-00187-1"},{"issue":"25","key":"e_1_3_3_43_1","first-page":"S37","article-title":"Effects of once-daily opicapone on duration of overnight off and time to morning on in patients with Parkinson\u2019s disease and motor fluctuations","volume":"88","author":"Hauser RALM","year":"2020","unstructured":"Hauser RALM , VidenovicA, PoeweQet al. Effects of once-daily opicapone on duration of overnight off and time to morning on in patients with Parkinson\u2019s disease and motor fluctuations. Ann. Neurol., 88(Suppl.25), S37 (2020).","journal-title":"Ann. Neurol."},{"issue":"2","key":"e_1_3_3_44_1","first-page":"S1","article-title":"Effect of opicapone and entacapone on early morning-off pattern in Parkinson\u2019s disease patients with motor fluctuations","volume":"34","author":"Videnovic APW","year":"2020","unstructured":"Videnovic APW , LeesA, FerreiraJJet al. Effect of opicapone and entacapone on early morning-off pattern in Parkinson\u2019s disease patients with motor fluctuations. Mov. Disord., 34(Suppl. S2), S1\u2013S937 (2020).","journal-title":"Mov. Disord."},{"issue":"25","key":"e_1_3_3_45_1","first-page":"S187","article-title":"Long-term efficacy of opicapone in the reduction of on-time with troublesome dyskinesia in Parkinson\u2019s disease patients with motor fluctuations and reporting troublesome dyskinesia","volume":"88","author":"Stocchi FFJ","year":"2020","unstructured":"Stocchi FFJ , KlepitskayaO, Magalh\u00e3esD, RochaJF, Soares-da-SilvaP. Long-term efficacy of opicapone in the reduction of on-time with troublesome dyskinesia in Parkinson\u2019s disease patients with motor fluctuations and reporting troublesome dyskinesia. Ann. Neurol., 88(Suppl.25), S187 (2020).","journal-title":"Ann. Neurol."},{"issue":"2","key":"e_1_3_3_46_1","first-page":"S1","article-title":"Switching entacapone \u2018non-responders\u2019 to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARKI study","volume":"34","author":"Ferreira JJLA","year":"2019","unstructured":"Ferreira JJLA , PoeweP, RascolOet al. Switching entacapone \u2018non-responders\u2019 to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARKI study. Mov. Disord., 34(Suppl. S2), S1\u2013S937 (2019).","journal-title":"Mov. Disord."},{"issue":"1","key":"e_1_3_3_47_1","first-page":"S444","article-title":"Efficacy and safety of opicapone in Parkinson\u2019s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II","volume":"35","author":"Ebersbach GRO","year":"2020","unstructured":"Ebersbach GRO , FerreiraJJ, CostaR, RochaJF, Magalh\u00e3esD, Soares-da-SilvaP. Efficacy and safety of opicapone in Parkinson\u2019s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK-I and II. Mov. Disord., 35(Suppl. S1), S444 (2020).","journal-title":"Mov. Disord."},{"issue":"1","key":"e_1_3_3_48_1","first-page":"S445","article-title":"Opicapone\u2019s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson\u2019s disease: a post-hoc analysis of BIPARK-I and II","volume":"35","author":"Ebersbach GFJ","year":"2020","unstructured":"Ebersbach GFJ , AntoniniA, SantosAT, Magalh\u00e3esD, RochaJF, Soares-da-SilvaP. Opicapone\u2019s added benefit as a first-line adjunctive therapy to levodopa and when used promptly in the motor fluctuations spectrum of Parkinson\u2019s disease: a post-hoc analysis of BIPARK-I and II. Mov. Disord., 35(Suppl. S1), S445 (2020).","journal-title":"Mov. Disord."},{"key":"e_1_3_3_49_1","first-page":"191","article-title":"Evaluation of non-motor symptoms in opicapone treated Parkinson\u2019s disease patients: results from a double-blind, randomized, placebo-controlled study and open-label extension","volume":"22","author":"Oliveira C","year":"2015","unstructured":"Oliveira C , LeesA, FerreiraJet al. Evaluation of non-motor symptoms in opicapone treated Parkinson\u2019s disease patients: results from a double-blind, randomized, placebo-controlled study and open-label extension. Eur. J. Neurol., 22, 191 (2015).","journal-title":"Eur. J. Neurol."},{"issue":"2","key":"e_1_3_3_50_1","first-page":"S46","article-title":"Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials","volume":"34","author":"Hauser RRO","year":"2019","unstructured":"Hauser RRO , PoeweW, FerreiraJJet al. Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials. Mov. Disord., 34(Suppl. S2), S46 (2019).","journal-title":"Mov. Disord."},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202022"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13156"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.12921"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2020.105633"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1433659"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-191593"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i12.3509"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.0590051683.x"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/nmt-2021-0006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:48:51Z","timestamp":1716493731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/nmt-2021-0006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.2217\/nmt-2021-0006"],"URL":"https:\/\/doi.org\/10.2217\/nmt-2021-0006","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}